Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00884000
Other study ID # FE999905 CS07
Secondary ID 2008-004849-28
Status Completed
Phase Phase 3
First received April 17, 2009
Last updated July 16, 2012
Start date January 2010
Est. completion date July 2012

Study information

Verified date July 2012
Source Ferring Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority Israel: Ministry of HealthIsrael: Ethics CommissionUkraine: Ministry of HealthUkraine: State Pharmacological Center - Ministry of HealthRomania: National Medicines AgencyRomania: National Authority for Scientific ResearchPoland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsPoland: Ministry of HealthHungary: National Institute of PharmacyGermany: German Institute of Medical Documentation and InformationGermany: Ethics CommissionRussia: Ethics CommitteeRussia: FSI Scientific Center of Expertise of Medical ApplicationRussia: Ministry of Health of the Russian FederationRussia: Pharmacological Committee, Ministry of HealthIndia: Drugs Controller General of IndiaIndia: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This trial is set up to compare Zomacton to Genotropin for the treatment of growth hormone deficiency in children. The children will be treated for 1 year. Half of the patients will be treated with Genotropin and half with Zomacton. During this time they will be dosed every day by themselves or their parents at home in the evening. There will be 138 patients in the trial from age 3 to age 11. The patients cannot have been treated before with growth hormone and the patients must have a proven growth hormone deficiency, this will be shown by a specific test that will be performed before the trial in the local clinic and once during the trial. During the time of the treatment the patients will come to visit the clinic every 3 months. At these visits their heights will be measured, blood samples will be taken, physical examinations will be performed and questions about their health will be asked. At 2 times in the trial they will have a hand x-ray taken to measure the bone age. At the end of the trial the patients will stop the treatment and continue on one of the marketed products available to treat growth hormone deficiency.


Recruitment information / eligibility

Status Completed
Enrollment 165
Est. completion date July 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Both
Age group 3 Years to 11 Years
Eligibility Inclusion Criteria:

1. Signed informed consent

2. Children aged =3yrs old and not above 10 yrs for girls or 11 yrs for boys

3. Idiopathic growth hormone deficiency confirmed during the pre-screening period by a standard GH stimulation test (defined as peak level of <10ng/ml pr lower if so required by the country specific board(s)

4. Height SDS <-2 SD of ref value for CA

5. Height velocity SDSCA = 0 SD of ref value for at lease 6 months prior to pre-screening

6. Height recorded for at least 6 months but not more than 18 months of pre-screening

7. The difference between CA-BA= 1

8. A positive locally performed GH stimulation test (defined as a peak plasma level of<9ng/ml or lower if so required by the country specific board(s)) prior to the pre-screening

Exclusion Criteria:

1. BA above 9 yrs for girls and 10 yrs for boys

2. Puberty Tanner stage >1

3. Weight <12 Kg at screening

4. Any prior treatment with GH

5. Closed epiphysis

6. Any diagnosed or suspected syndrome (e.g. Silver -Russell, Turner's or seckel syndrome) which possibly could affect growth

7. Any other diagnosed or suspected endocrine or metabolic disorder

8. Any diagnosed or suspected sever chronic disease

9. Clinical signs of dysmorphic features, malformations or mental retardations

10. Growth failure due to other disorders

11. Previous or present use of drugs that could interfere with GH treatment (e.g. steroids)

12. Diagnosed malignant disease

13. Any abnormal CS lab results that requires further investigation

14. Receipt of an investigational drug within the last 28 days preceding screening or longer if considered possible to influence the outcome of the current trial

15. Any knowledge of hypersensitivity to somatropin or any of the excipients of Zomacton or Genotropin

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Genotropin

Zomacton


Locations

Country Name City State
Hungary Semmelweiss University, 1st dept of paediatrics Budapest
Hungary Szent Janos Kh Budai Budapest
Hungary Petz Country Teaching Hospital Gyor
Hungary University of Szeged Szeged
Hungary Markusovszkty Teaching Hospital Szombathely
India Associates in Clinical Endocrinology Education and Research (ACEER) Chennai
India Apollo Hospitals Hyderabad
India TOTALL Diabetes Hormone Institute Indore
India KEM Hospital Mumbai
India Prince Aly Khan Hospital Mumbai
India Endocare Clinic Nasik
India Jehangir Clinical Development Centre Pvt. Ltd., Jehangir Hospital Pune
India Health & Research Centre Trivandrum
Israel Haemek Medical Center Afula
Israel Soroka University Medical Center Beer Sheva
Israel Western Galilee Medical Center Nahariya
Israel Schneider Children's Medical Center of Israel Petach Tikva
Israel Edmond and Lily Safra Children's hospital - The Chaim Sheba Medical Center Ramat Gan
Israel Kaplan Medical Center Rehovot
Israel Dana Children's Hospital - Tel-Aviv Sourasky Medical Center Tel Aviv
Poland Wojewódzki Szpital Dzieciecy im. J.Brudzinskiego w Bydgoszczy Bydgoszcz
Poland Uniwersyteckie Centrum Kliniczne, Gdansk Gdansk
Poland Uniwersytecki Szpital Dzieciecy w Krakowie Krakow
Poland SPSK nr.1 im. Prof. T. Sokolowskiego PAM Szczecin Szczecin
Romania Societatea Civila Medicala "Dr. Paveliu" Bucuresti
Romania Spitalul Clinic Municipal "Filantropia" Craiova
Romania Spitalul Clinic Judetean de Urgenta "Sf. Spiridon" Iasi
Romania Spitalul Clinic Judetean Mures Targu Mures
Romania Paediatric Endocrinology/Medicali's SRL Timisoara
Romania Spitalul Clinic pentru Copii Louis Turcanu Timisoara
Russian Federation State Educational Institution of Higher Professional Education "Kazan State Medical University of ROSZDRAV Kazan
Russian Federation Federal State Institution Moscow
Russian Federation Russian Medical Academy of Post-graduate Education Moscow
Russian Federation Saint-Petersburg State Health Care Institution Saint Petersburg
Russian Federation State Educational Institution for Higher Professional Education Saratov
Russian Federation State Educational Institution of Higher Professional Education "Siberian State Medical University of ROSZDRAV Tomsk
Ukraine Donetsk Regional Clinical Children's Hospital Donetsk
Ukraine Ivano-Frankivsk Regional Children Clinical Hospital Ivano-Frankivsk
Ukraine Kharkiv Regional Clinical Children's Hospital Kharkiv
Ukraine Institute of Endocrinology and Metabolism Kiev
Ukraine Ukrainian Children's Specialized Clinical Hospital Kiev
Ukraine Odessa National Medical University - (Located at Odessa Region Children's Clinical Hospital) Odessa
Ukraine Zaporizhzhya Regional Paediatric Hospital Zaporizhya

Sponsors (1)

Lead Sponsor Collaborator
Ferring Pharmaceuticals

Countries where clinical trial is conducted

Hungary,  India,  Israel,  Poland,  Romania,  Russian Federation,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Height Velocity 12 months No
Secondary Height SDS 12 months No
Secondary Height velocity SDS 12 months No
Secondary Change in IGF-1 and IGFBP-3 12 months No
Secondary BA (Bone Age) 12 months No
Secondary Anti-hGH AB 12 months Yes
Secondary AE and tolerability 12 months Yes
Secondary CS Changes in safety lab, physical examination and vital signs 12 months Yes
See also
  Status Clinical Trial Phase
Recruiting NCT02243852 - Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21) N/A
Completed NCT01440686 - Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Phase 1
Completed NCT00990340 - Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Phase 4
Completed NCT00149708 - Consequence of Lifetime Isolated Growth Hormone Deficiency N/A
Completed NCT00235599 - The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children. N/A
Completed NCT00459940 - The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients N/A
Completed NCT01157793 - A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Phase 4
Completed NCT00004365 - Study of Pituitary Size and Function in Familial Dwarfism of Sindh N/A
Recruiting NCT00227253 - Chromosome 18 Clinical Research Center
Recruiting NCT04121780 - Growth Hormone Replacement Therapy for Retried Professional Football Players Phase 2
Completed NCT02934399 - Dynamic Hormone Diagnostics in Endocrine Disease
Completed NCT01090778 - Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I) Phase 2
Completed NCT00965484 - Genotropin Study Assessing Use of Injection Pen Phase 3
Completed NCT01062529 - Peripheral Metabolic Effects of Somatostatin N/A
Completed NCT00616278 - National Cooperative Growth Study in CKD N/A
Completed NCT02693522 - Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency Phase 3
Recruiting NCT02908958 - Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Phase 4
Terminated NCT01243892 - A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device N/A
Withdrawn NCT00638287 - Inter-Assay Growth Hormone and IGF-I Variability N/A
Completed NCT00929799 - Growth Hormone and Glucose Metabolism Phase 4